NIVF
Income statement / Annual
Last year (2023), NewGenIvf Group Limited's total revenue was $5.14 M,
a decrease of 13.59% from the previous year.
In 2023, NewGenIvf Group Limited's net income was -$690,851.00.
See NewGenIvf Group Limited’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$5.14 M
|
$5.94 M
|
$4.12 M
|
| Cost of Revenue |
$3.45 M |
$4.41 M |
$3.09 M |
| Gross Profit |
$1.68 M |
$1.54 M |
$1.02 M |
| Gross Profit Ratio |
0.33 |
0.26 |
0.25 |
| Research and Development
Expenses |
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$1.62 M
|
$1.10 M
|
$801,329.00
|
| Selling & Marketing
Expenses |
$18,030.00
|
$36,194.00
|
$24,693.00
|
| Selling, General &
Administrative Expenses |
$2.52 M
|
$504,907.00
|
$826,022.00
|
| Other Expenses |
$0.00 |
$23,019.00 |
$45,652.00 |
| Operating Expenses |
$2.52 M |
$504,907.00 |
$826,022.00 |
| Cost And Expenses |
$5.09 M |
$504,907.00 |
$3.92 M |
| Interest Income |
$518.00 |
$21.00 |
$63.00 |
| Interest Expense |
$46,179.00 |
$77,757.00 |
$88,289.00 |
| Depreciation &
Amortization |
$229,708.00
|
$303,944.00
|
$342,539.00
|
| EBITDA |
-$2.52 M
|
-$504,909.00
|
$587,012.00
|
| EBITDA Ratio |
-0.49 |
-0.08 |
0.14 |
| Operating Income Ratio
|
0.01
|
-0.08
|
0.05
|
| Total Other
Income/Expenses Net |
-$733,093.00
|
-$54,717.00
|
-$42,574.00
|
| Income Before Tax |
-$690,851.00 |
$500,650.00 |
$156,184.00 |
| Income Before Tax Ratio
|
-0.13
|
0.08
|
0.04
|
| Income Tax Expense |
-$799,269.00 |
$208,141.00 |
$294,716.00 |
| Net Income |
-$690,851.00 |
$458,667.00 |
-$533.00 |
| Net Income Ratio |
-0.13 |
0.08 |
-0 |
| EPS |
-0.13 |
0.0646 |
-0.0001 |
| EPS Diluted |
-0.13 |
0.0646 |
-0.0001 |
| Weighted Average Shares
Out |
$5.43 M
|
$7.75 M
|
$10.15 M
|
| Weighted Average Shares
Out Diluted |
$5.43 M
|
$7.75 M
|
$10.15 M
|
| Link |
|
|
|
